Replimune Group, Inc.

NASDAQ:REPL

Biotechnology

Healthcare
$19.81 +1.85%

+$0.19 today

Market cap
$1.88B
Beta
0.91
P/E (TTM)
-3.0
EPS (TTM)
-$3.42
52W Low $1.50High $13.24

Volume 2.13M

Average 7.51M

REPL Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Replimune Group, Inc.NASDAQ: REPL

Net Change in Cash · Q3 FY2026 · quarter ended Dec 2025

Net change in cash declines year over year

Q3 FY2026 net change in cash of $20.65M fell 64.8% year over year, ahead of the -166.1% change in trailing-twelve-month net change in cash. Sequentially, it rose 319.5% from the prior quarter.

Context

  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -64.8% holds above the trailing-twelve-month pace of -166.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$20.65M+319.5% QoQ
Last fiscal yearMar 2025
$36.67M+150.9% YoY
LTMDec 2025
-$49.29M-166.1% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-64.8%——
1 year+150.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
36.67M USD
Year-over-year change
+150.9%
4-year CAGR
-26.1%

Net Change in Cash vs competitors

How REPL compares with its peers on the latest reported figures

  • REPL's LTM Dec 2025 net change in cash of $49.29M is the 6th largest of the 11 companies compared; the peer median is $20.1M.
  • Its year-over-year change of -166.1% is the 7th highest of 9, against a peer median of +36.1%.
REPL Competitors Peer median
Net Change in Cash for REPL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$641.62M +3223.9%—91.4%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$284.68M +4316.4%-32.5%75.1%
ADAGAdagene Inc.LTM Jun 2024$161.85M —-29.6%19840.3%
MGNXMacroGenics, Inc.LTM Mar 2026$79.05M -221.2%+105.0%50.3%
CGENCompugen Ltd.LTM Dec 2025$72.37M —+192.0%99.5%
REPLReplimune Group, Inc.LTM Dec 2025$49.29M -166.1%——
LYELLyell Immunopharma, Inc.LTM Mar 2026$29.66M +457.2%-35.6%95683.9%
JANXJanux Therapeutics, Inc.LTM Mar 2026$21.92M -84.2%—101.4%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$18.28M -258.5%+28.0%51.4%
IBRXImmunityBio, Inc.LTM Sep 2026$15.16M -70.3%-10.6%8.3%
AGENAgenus Inc.LTM Mar 2026$14.59M +142.4%-31.9%11.8%
Peer median (excluding REPL) $20.1M+36.1%-20.1%83.3%

Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Net Income(80.87M)(118.04M)(174.28M)(215.79M)(247.3M)
Depreciation & Amortization1.71M2.15M2.45M2.66M3.5M
Deferred Income Tax0038K00
Stock-Based Compensation11.79M24.25M28.13M34.13M35.04M
Change in Working Capital3.51M7.24M15.12M5.48M24.08M
Accounts Receivables325K(247K)(61K)(1.92M)1.3M
Inventory0247K61K00
Accounts Payables(1.03M)1.12M1.98M(2.79M)9.94M
Other Working Capital4.22M6.12M13.14M10.19M12.84M
Other Non-Cash Items2.47M2.22M494K(11.94M)(7.58M)
Operating Cash Flow(61.39M)(82.18M)(128.05M)(185.47M)(192.25M)
Capital Expenditures(2.39M)(2.34M)(2.27M)(5.66M)(6.69M)
Acquisitions (Net)0(530)140.23K00
Purchases of Investments(392.43M)(255.72M)(583.41M)(489.52M)(403.59M)
Sales of Investments206.05M256.25M443.18M592.38M386.48M
Other Investing Activities0530(140.23K)00
Investing Cash Flow(188.78M)(1.81M)(142.5M)97.2M(23.8M)
Debt Repayment(10.15M)(264K)27.79M14.52M(599K)
Common Stock Issued286.11M6.86M187.29M1.76M155.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities96.5M096.22M097.27M
Financing Cash Flow372.46M6.6M311.3M16.28M252.4M
Effect of Forex Changes721K818K(109K)(86K)315K
Net Change in Cash123.02M(76.57M)40.64M(72.07M)36.67M
Free Cash Flow(63.78M)(84.52M)(130.32M)(191.13M)(198.94M)

Replimune Group, Inc.

NASDAQ:REPL

Intrinsic Alpha fair value

Locked

Current Price

$19.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.